[Infectious complications in liver transplant in Italy: current status and prospectives].
The impact of infections in orthotopic liver transplantation (OLT) is remarkable. Studies have shown that about 60% of patient may develop at least 1 infectious episode during the first 3 months after transplant. Within the frame of a Finalized Research Project of the Italian Ministry of Health, during the year 2000 a group of investigators belonging to the major Italian Liver Transplant Centers (LTC)--18 out of 20 Centers--met three times in Genoa with the aim of constituting a Research Group aimed at improving our knowledge of infectious complications in liver transplant recipients (PITF = Program of Infections in Liver Transplantation). The group first collected information about anti-infective procedure in LTC. The study shows that no Center is supported by a Intensive Care Unit (ICU) exclusively dedicated to the LTC, although 37% of them have a partially dedicated Unit. Surveillance cultures are routinely performed and are frequently used to address the choice of the antibacterial and antifungal regimes. Selective Bowel Decontamination is also very common. The management of CMV infection is usually performed as indicated in international guidelines.
Viscoli
C
C
Dipartimento di Oncologia, Biologia e Genetica, Istituto Nazionale per la Ricerca sul Cancro, Genova. viscoli@unige.it
Dimitri
P
P
Di Domenico
S
S
Mannelli
S
S
Dodi
F
F
Veroni
L
L
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001424:Bacterial Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D001649:Bile Duct Diseases / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects*; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D016730:Program Development; D015397:Program Evaluation; D014777:Virus Diseases / Q000150:complications* / Q000188:drug therapy / Q000821:virology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000998:Antiviral Agents